PLUS THERAPEUTICS, INC.
For the period ended Jun 30, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 14, 2025
CNSY$0.68+19.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| For the Six Months Ended June 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows used in operating activities: | ||
| Net loss | $(12,250) | $(6,201) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 223 | 325 |
| Amortization of deferred financing costs and debt discount | — | 20 |
| Share-based compensation expense | 300 | 297 |
| Noncash financing expenses | 3,061 | 3,545 |
| Change in fair value of derivative instruments | 2,631 | (4,694) |
| Accretion of discount on short-term investments | (22) | (23) |
| Reduction in the carrying amount of operating lease right-of-use assets | 44 | 63 |
| Gain on sale of assets | (16) | — |
| Increases (decreases) in cash caused by changes in operating assets and liabilities: | ||
| Grant receivable | (450) | — |
| Other current assets | (265) | 335 |
| Accounts payable and accrued expenses | (5,181) | 360 |
| Change in operating lease liabilities | (45) | (63) |
| Deferred grant liability | — | 373 |
| Net cash used in operating activities | (11,970) | (5,663) |
| Cash flows used in investing activities: | ||
| Purchases of property and equipment | (10) | (121) |
| Purchase of short-term investments | (7,756) | (3,500) |
| Redemption of short-term investments | 6,662 | — |
| Purchase of intangible assets | — | (545) |
| Proceeds from sale of property and equipment | 30 | — |
| Net cash used in investing activities | (1,074) | (4,166) |
| Cash flows provided by financing activities: | ||
| Principal payments of term loan obligation | — | (3,996) |
| Proceeds from credit facility | — | 3,292 |
| Repayment of line of credit facility | (3,292) | — |
| Repayment of notes payable | (3,703) | — |
| Issuance of notes payable and warrants | 3,738 | — |
| Proceeds from exercise of Series B Warrants from May 2024 PIPE | 882 | — |
| Purchase of treasury stock | — | (374) |
| Proceeds from sale of common stock, pre-funded warrants and warrants | 15,001 | 7,310 |
| Proceeds from sale of common stock under Lincoln Park Purchase Agreement | 2,795 | — |
| Costs from sale of common stock | (220) | (45) |
| Net cash provided by financing activities | 15,201 | 6,187 |
| Net increase (decrease) in cash and cash equivalents | 2,157 | (3,642) |
| Cash and cash equivalents at beginning of period | 76 | 8,554 |
| Cash and cash equivalents at end of period | $2,233 | $4,912 |
| Supplemental disclosure of cash flows information: | ||
| Cash paid during period for: | ||
| Interest | $539 | $32 |
| Supplemental schedule of non-cash investing and financing activities: | ||
| Exchange of warrants for notes payable | $3,694 | $— |
| Redemption of notes by issuance of common stock, pre-funded warrants and warrants | $3,512 | $— |
| Unpaid offering cost | $252 | $375 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.